2022
Optimizing the Design and Analysis of Future AKI Trials
Legrand M, Bagshaw SM, Koyner JL, Schulman IH, Mathis MR, Bernholz J, Coca S, Gallagher M, Gaudry S, Liu KD, Mehta RL, Pirracchio R, Ryan A, Steubl D, Stockbridge N, Erlandsson F, Turan A, Wilson FP, Zarbock A, Bokoch MP, Casey JD, Rossignol P, Harhay MO. Optimizing the Design and Analysis of Future AKI Trials. Journal Of The American Society Of Nephrology 2022, 33: 1459-1470. PMID: 35831022, PMCID: PMC9342638, DOI: 10.1681/asn.2021121605.Peer-Reviewed Original ResearchConceptsAKI trialsClinical trialsTrial participantsTrial designAKI clinical trialsPerioperative patient populationsComplex clinical syndromeRisk of morbidityPragmatic trial designTreatment effectsClinical trial planningImportant treatment effectsClinical trial analysisAKI preventionClinical courseClinical syndromePatient populationTrial interventionClinical questionsClinical trialistsAKITrial infrastructureTrial planningTrialsEfficient enrollment
2016
Application of new acute kidney injury biomarkers in human randomized controlled trials
Parikh CR, Moledina DG, Coca SG, Thiessen-Philbrook HR, Garg AX. Application of new acute kidney injury biomarkers in human randomized controlled trials. Kidney International 2016, 89: 1372-1379. PMID: 27165835, PMCID: PMC4869991, DOI: 10.1016/j.kint.2016.02.027.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAKI biomarkersKidney injuryClinical trialsNew biomarkersEarly acute kidney injuryObserved relative risk reductionPostoperative acute kidney injuryAcute kidney injury biomarkersHypothetical trialKidney injury progressionMulti-country trialAcute tubular necrosisCardiopulmonary bypass timeClinical risk factorsKidney injury biomarkersProportion of patientsProspective cohort studyKidney injury markersRelative risk reductionAKI progressionAKI trialsBypass timeCohort studyInjury markers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply